5-(3,5-Dimethylphenyl)-1-methylpyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(3,5-Dimethylphenyl)-1-methylpyrazole
• 英文别名: 5-(3,5-dimethylphenyl)-1-methylpyrazole
• 化学式: C₁₂H₁₄N₂
• 分子量: 186.25
• InChiKey: ZRKKWJNXFXBJDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180208560A1

  公开（公告）日：2018-07-26

  The present invention relates to compounds of formula I, wherein the groups R, R 1 , R 2 , R 3 , m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

  本发明涉及化合物I的公式，其中R、R1、R2、R3、m和n所定义的基团在此处被定义，具有有价值的药理特性，特别是与GPR40受体结合并调节其活性。这些化合物适用于治疗和预防受这种受体影响的疾病，如代谢性疾病，特别是2型糖尿病。此外，该发明涉及用于合成化合物I的新型中间体。
• INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180148411A1

  公开（公告）日：2018-05-31

  The present invention relates to compounds of general formula I, wherein the groups R, R 1 , R 2 , R 3 , m and n are as defined herein, which compounds have valuable pharmacological properties, in particular their ability to bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular type 2 diabetes. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

  本发明涉及一般式I的化合物，其中R、R1、R2、R3、m和n的基团如本文所定义，这些化合物具有有价值的药理学特性，特别是它们与GPR40受体结合并调节其活性的能力。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。此外，本发明涉及用于合成一般式I化合物的新型中间体。
• Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10793530B2

  公开（公告）日：2020-10-06

  The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及通式 I 的化合物、 其中基团 R、R1、R2、R3、m 和 n 在此定义，它们具有宝贵的药理特性，尤其能与 GPR40 受体结合并调节其活性。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，尤其是 2 型糖尿病。
• Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10919859B2

  公开（公告）日：2021-02-16

  The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及通式 I 的化合物、 其中基团 R、R1、R2、R3、m 和 n 在本文中定义，它们具有重要的药理特性，尤其能与 GPR40 受体结合并调节其活性。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，尤其是 2 型糖尿病。
• US9617251B2
  申请人：——

  公开号：US9617251B2

  公开（公告）日：2017-04-11